Prepared by a licensed compounding pharmacy. Not FDA-approved.
Semaglutide is a GLP-1 medication. It works by mimicking a natural hormone (GLP-1) that reduces appetite and helps the body regulate blood sugar. LightWeightMD offers compounded semaglutide, prepared by a licensed Florida compounding pharmacy and prescribed only after a live consultation with a licensed provider. Compounded medications are not FDA-approved.
Treatment starts at a low dose and steps up over roughly four months. The slow ramp is deliberate: most side effects appear when a dose climbs too fast, and giving your body time to adjust keeps the majority of people comfortable. Your provider sets your actual schedule.
GLP-1 is a hormone your gut releases after you eat. It tells your pancreas to release insulin, slows how quickly your stomach empties, and signals your brain that you are satisfied. Natural GLP-1 breaks down within minutes; semaglutide is built to do the same job and last about a week per dose. Most people describe two changes: feeling full sooner and staying full longer, and a noticeable drop in the mental chatter about food.
Nausea, constipation, and fatigue are the most commonly reported, and usually ease as your body adjusts. They tend to show up after a dose increase. Smaller meals, eating slowly, and drinking more water than feels necessary are the three habits that help most.
Contact your provider promptly for severe abdominal pain that will not let up, persistent vomiting, or signs of an allergic reaction. These are uncommon but should be taken seriously.
Compounded semaglutide is $200 per month through LightWeightMD, including medication, shipment, and ongoing physician oversight. Your first month is $149. The price stays $200 until 2.5 mg, when it becomes $230. There is no membership fee. See the schedule.
Compounded medications are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality. Read our guide to compounding for the full picture.
Comparing options? Read about compounded tirzepatide.